MétaCan
Menu
Back to cohort
Record W3178615988 · doi:10.1093/narcan/zcab028

Characterization of a <i>RAD51C</i> -silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance

2021· article· en· W3178615988 on OpenAlexfundno aff
Rachel M. Hurley, Cordelia D. McGehee, Ksenija Nesic, Cristina Correia, Taylor M. Weiskittel, Rebecca L. Kelly, Annapoorna Venkatachalam, Xiaonan Hou, Nicholas M. Pathoulas, X. Wei Meng, Olga Kondrashova, Marc R. Radke, Paula A. Schneider, Karen S. Flatten, Kevin L. Peterson, Marc A. Becker, Ee Ming Wong, Melissa S Southey, Alexander Dobrovic, Kevin Lin, Thomas C. Harding, Iain A. McNeish, Christian Roß, Jill M. Wagner, Matthew J. Wakefield, Clare L. Scott, Paul Haluska, Andrea E. Wahner Hendrickson, Larry M. Karnitz, Elizabeth M. Swisher, Hu Li, S. John Weroha, Scott H. Kaufmann

Bibliographic record

VenueNAR Cancer · 2021
Typearticle
Languageen
FieldMedicine
TopicPARP inhibition in cancer therapy
Canadian institutionsnot available
FundersNational Cancer InstituteStand Up To CancerNational Institutes of HealthMayo Foundation for Medical Education and ResearchSierra OncologyNational Institute of General Medical SciencesNational Institute for Health and Care ResearchEisaiBeiGeneNational Breast Cancer FoundationClovis OncologyOvarian Cancer Research AllianceAstraZeneca
KeywordsCancer researchOvarian cancerPARP inhibitorMethylationBiologyMedicineCancerOncologyInternal medicinePoly ADP ribose polymeraseGeneGeneticsPolymerase

Abstract

fetched live from OpenAlex

Abstract Acquired PARP inhibitor (PARPi) resistance in BRCA1- or BRCA2-mutant ovarian cancer often results from secondary mutations that restore expression of functional protein. RAD51C is a less commonly studied ovarian cancer susceptibility gene whose promoter is sometimes methylated, leading to homologous recombination (HR) deficiency and PARPi sensitivity. For this study, the PARPi-sensitive patient-derived ovarian cancer xenograft PH039, which lacks HR gene mutations but harbors RAD51C promoter methylation, was selected for PARPi resistance by cyclical niraparib treatment in vivo. PH039 acquired PARPi resistance by the third treatment cycle and grew through subsequent treatment with either niraparib or rucaparib. Transcriptional profiling throughout the course of resistance development showed widespread pathway level changes along with a marked increase in RAD51C mRNA, which reflected loss of RAD51C promoter methylation. Analysis of ovarian cancer samples from the ARIEL2 Part 1 clinical trial of rucaparib monotherapy likewise indicated an association between loss of RAD51C methylation prior to on-study biopsy and limited response. Interestingly, the PARPi resistant PH039 model remained platinum sensitive. Collectively, these results not only indicate that PARPi treatment pressure can reverse RAD51C methylation and restore RAD51C expression, but also provide a model for studying the clinical observation that PARPi and platinum sensitivity are sometimes dissociated.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.021
Threshold uncertainty score0.898

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.026
GPT teacher head0.292
Teacher spread0.266 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations36
Published2021
Admission routes1
Has abstractyes

Explore more

Same venueNAR CancerSame topicPARP inhibition in cancer therapyFrench-language works237,207